70 results on '"Sirbu C."'
Search Results
2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
- Author
-
Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., Duquette P., Onofrj M., Lugaresi A., Grand'Maison F., Grammond P., Sola P., Ferraro D., Terzi M., Gerlach O., Alroughani R., Boz C., Shaygannejad V., van Pesch V., Cartechini E., Kappos L., Lechner-Scott J., Bergamaschi R., Turkoglu R., Solaro C., Iuliano G., Granella F., Van Wijmeersch B., Spitaleri D., Slee M., McCombe P., Prevost J., Ampapa R., Ozakbas S., Sanchez-Menoyo J., Soysal A., Vucic S., Petersen T., de Gans K., Butler E., Hodgkinson S., Sidhom Y., Gouider R., Cristiano E., Castillo-Trivino T., Saladino M., Barnett M., Moore F., Rozsa C., Yamout B., Skibina O., van der Walt A., Buzzard K., Gray O., Hughes S., Sempere A.P., Singhal B., Fragoso Y., Shaw C., Kermode A., Taylor B., Simo M., Shuey N., Al-Harbi T., Macdonell R., Dominguez J.A., Csepany T., Sirbu C., Sormani M.P., Butzkueven H., Kalincik T., Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., Duquette P., Onofrj M., Lugaresi A., Grand'Maison F., Grammond P., Sola P., Ferraro D., Terzi M., Gerlach O., Alroughani R., Boz C., Shaygannejad V., van Pesch V., Cartechini E., Kappos L., Lechner-Scott J., Bergamaschi R., Turkoglu R., Solaro C., Iuliano G., Granella F., Van Wijmeersch B., Spitaleri D., Slee M., McCombe P., Prevost J., Ampapa R., Ozakbas S., Sanchez-Menoyo J., Soysal A., Vucic S., Petersen T., de Gans K., Butler E., Hodgkinson S., Sidhom Y., Gouider R., Cristiano E., Castillo-Trivino T., Saladino M., Barnett M., Moore F., Rozsa C., Yamout B., Skibina O., van der Walt A., Buzzard K., Gray O., Hughes S., Sempere A.P., Singhal B., Fragoso Y., Shaw C., Kermode A., Taylor B., Simo M., Shuey N., Al-Harbi T., Macdonell R., Dominguez J.A., Csepany T., Sirbu C., Sormani M.P., Butzkueven H., and Kalincik T.
- Abstract
Background and purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. Method(s): In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. Result(s): The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score >1.5). Conclusion(s): Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.Copyright © 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behal
- Published
- 2022
3. Echocardiographic predictors of outcome after isolated tricuspid valvular surgery
- Author
-
Eggenspieler, F, primary, Huttin, O, additional, Erpelding, ML, additional, Filippetti, L, additional, Pace, N, additional, Popovic, B, additional, Sirbu, C, additional, Elfarra, M, additional, Maureira, P, additional, and Selton Suty, C, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Poster session 2: Thursday 4 December 2014, 08: 30–12: 30Location: Poster area
- Author
-
Sirbu, C F, Berrebi, A, Huber, A, and Folliguet, T
- Published
- 2014
5. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
- Author
-
Kalincik, T, Diouf, I, Sharmin, S, Malpas, C, Spelman, T, Horakova, D, Havrdova, EK, Trojano, M, Izquierdo, G, Lugaresi, A, Prat, A, Girard, M, Duquette, P, Grammond, P, Jokubaitis, V, Van der Walt, A, Grand'Maison, F, Sola, P, Ferraro, D, Shaygannejad, V, Alroughani, R, Hupperts, R, Terzi, M, Boz, C, Lechner-Scott, J, Pucci, E, Van Pesch, V, Granella, F, Bergamaschi, R, Spitaleri, D, Slee, M, Vucic, S, Ampapa, R, McCombe, P, Ramo-Tello, C, Prevost, J, Olascoaga, J, Cristiano, E, Barnett, M, Saladino, ML, Sanchez-Menoyo, JL, Hodgkinson, S, Rozsa, C, Hughes, S, Moore, F, Shaw, C, Butler, E, Skibina, O, Gray, O, Kermode, A, Csepany, T, Singhal, B, Shuey, N, Piroska, I, Taylor, B, Simo, M, Sirbu, C-A, Sas, A, Butzkueven, H, Kalincik, T, Diouf, I, Sharmin, S, Malpas, C, Spelman, T, Horakova, D, Havrdova, EK, Trojano, M, Izquierdo, G, Lugaresi, A, Prat, A, Girard, M, Duquette, P, Grammond, P, Jokubaitis, V, Van der Walt, A, Grand'Maison, F, Sola, P, Ferraro, D, Shaygannejad, V, Alroughani, R, Hupperts, R, Terzi, M, Boz, C, Lechner-Scott, J, Pucci, E, Van Pesch, V, Granella, F, Bergamaschi, R, Spitaleri, D, Slee, M, Vucic, S, Ampapa, R, McCombe, P, Ramo-Tello, C, Prevost, J, Olascoaga, J, Cristiano, E, Barnett, M, Saladino, ML, Sanchez-Menoyo, JL, Hodgkinson, S, Rozsa, C, Hughes, S, Moore, F, Shaw, C, Butler, E, Skibina, O, Gray, O, Kermode, A, Csepany, T, Singhal, B, Shuey, N, Piroska, I, Taylor, B, Simo, M, Sirbu, C-A, Sas, A, and Butzkueven, H
- Abstract
OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. METHODS: We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity. RESULTS: A total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43-0.82, p = 0.0016), worsening of disability (0.56, 0.38-0.82, p = 0.0026), and progress to EDSS step 6 (0.33, 0.19-0.59, p = 0.00019). Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50-0.70, p = 10-9) and worsening of disability (0.81, 0.67-0.99, p = 0.043). CONCLUSION: Continued treatment with MS immunotherapies reduces disability accrual by 19%-44% (95% CI 1%-62%), the risk of need of a walking aid by 67% (95% CI 41%-81%), and the frequency of relapses by 40-41% (95% CI 18%-57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.
- Published
- 2021
6. Effect of disease modifying therapy on disability in Relapsing-Remitting multiple sclerosis over 15 Years
- Author
-
Kalincik, T., Diouf, I., Sharmin, S., Malpas, C., Spelman, T., Horakova, D., Havrdova, E.K., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Jokubaitis, V., Van der Walt, A., Grand'Maison, F., Sola, P., Ferraro, D., Shaygannejad, V., Alroughani, R., Hupperts, R., Terzi, M., Boz, C., Lechner-Scott, J., Pucci, E., van Pesch, V., Granella, F., Bergamaschi, R., Spitaleri, D., Slee, M., Vucic, S., Ampapa, R., McCombe, P., Ramo-Tello, C., Prevost, J., Olascoaga, J., Cristiano, E., Barnett, M., Saladino, M.L., Sanchez-Menoyo, J.L., Hodgkinson, S., Rózsa, C., Hughes, S., Moore, F., Shaw, C., Butler, E., Skibina, O., Gray, O., Kermode, A., Csepany, T., Singhal, B., Shuey, N., Piroska, I., Taylor, B., Simon, M., Sirbu, C-A, Sas, A., Butzkueven, H., Kalincik, T., Diouf, I., Sharmin, S., Malpas, C., Spelman, T., Horakova, D., Havrdova, E.K., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Jokubaitis, V., Van der Walt, A., Grand'Maison, F., Sola, P., Ferraro, D., Shaygannejad, V., Alroughani, R., Hupperts, R., Terzi, M., Boz, C., Lechner-Scott, J., Pucci, E., van Pesch, V., Granella, F., Bergamaschi, R., Spitaleri, D., Slee, M., Vucic, S., Ampapa, R., McCombe, P., Ramo-Tello, C., Prevost, J., Olascoaga, J., Cristiano, E., Barnett, M., Saladino, M.L., Sanchez-Menoyo, J.L., Hodgkinson, S., Rózsa, C., Hughes, S., Moore, F., Shaw, C., Butler, E., Skibina, O., Gray, O., Kermode, A., Csepany, T., Singhal, B., Shuey, N., Piroska, I., Taylor, B., Simon, M., Sirbu, C-A, Sas, A., and Butzkueven, H.
- Abstract
Objective To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. Methods We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity. Results A total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43–0.82, p = 0.0016), worsening of disability (0.56, 0.38–0.82, p = 0.0026), and progress to EDSS step 6 (0.33, 0.19–0.59, p = 0.00019). Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50–0.70, p = 10−9) and worsening of disability (0.81, 0.67–0.99, p = 0.043). Conclusion Continued treatment with MS immunotherapies reduces disability accrual by 19%–44% (95% CI 1%–62%), the risk of need of a walking aid by 67% (95% CI 41%–81%), and the frequency of relapses by 40–41% (95% CI 18%–57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. Classification of Evidence This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.
- Published
- 2020
7. Myalgic encephalomyelitis/chronic fatigue Syndrome (ME/CFS): Investigating care practices pointed out to disparities in diagnosis and treatment across European Union
- Author
-
Strand, Elin B., Nacul, Luis, Mengshoel, Anne Marit, Helland, Ingrid B., Grabowski, Patricia, Krumina, Angelika, Alegre Martín, José, Efrim-Budisteanu, Magdalena, Sekulic, Slobodan, Pheby, Derek, Sakkas, Giorgos K., Adella Sirbu, Carmen, Authier, François Jérôme, Murovska, Modra, Lacerda, Eliana, Estevez Lopez, Fernando, Scheibenbogen, C., Shi-Kova-Lekova, E., Lorusso, Lorenzo, Berkis, U., Westermeier, F., Riederer, M., Tobback, E., Meeus, Mira, Shikova-Lekova, E., Nielsen, H., Brandslund, I., Polo, O., De Korwin, J. D., Harrer, T., Prusty, B., Freitag, H., Trepel, D., Cullinan, John, Capelli, Enrica, Nora-Krukle, Z., Rasa, S., Vermeulen, R., Menhshoel, A. M., Helland, I. B., Zalewski, Paweł, Sepulveda, N., Sirbu, C. A., Vukadinovic, M., Marusic, U., Pisot, R., Castro-Marrero, Jesús., Blanco, Julià, Oltra, E., Miro, J., Berquist, J., Blomberg, J., Pheby, D., Edwards, J., Wang, X., and Universitat Autònoma de Barcelona
- Subjects
Male ,Coping (psychology) ,diagnosis ,medicine.medical_treatment ,Disease ,Pathology and Laboratory Medicine ,chronic fatigue syndrome ,Geographical locations ,0302 clinical medicine ,Public health surveillance ,Surveys and Questionnaires ,Medicine and Health Sciences ,Public Health Surveillance ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Fatigue ,media_common ,Netherlands ,0303 health sciences ,Multidisciplinary ,Fatigue Syndrome, Chronic ,treatment ,Depression ,Disease Management ,Research Assessment ,Cognitive behavioral therapy ,Europe ,myalgic encephalomyelitis ,Practice Guidelines as Topic ,Medicine ,Female ,ME/CFS ,Research Article ,medicine.medical_specialty ,Science ,MEDLINE ,Research and Analysis Methods ,03 medical and health sciences ,Signs and Symptoms ,Diagnostic Medicine ,Mental Health and Psychiatry ,Chronic fatigue syndrome ,medicine ,media_common.cataloged_instance ,Humans ,European Union ,European union ,Healthcare Disparities ,030304 developmental biology ,Treatment Guidelines ,Health Care Policy ,business.industry ,Mood Disorders ,medicine.disease ,Health Care ,Psychotherapy ,Family medicine ,Quality of Life ,People and places ,business ,Mental Health Therapies ,Delivery of Health Care - Abstract
ME/CFS is a chronic, complex, multisystem disease that often limits the health and functioning of the affected patients. Diagnosing patients with ME/CFS is a challenge, and many different case definitions exist and are used in clinical practice and research. Even after diagnosis, medical treatment is very challenging. Symptom relief and coping may affect how patients live with their disease and their quality of life. There is no consensus on which diagnostic criteria should be used and which treatment strategies can be recommended for patients. The purpose of the current project was to map the landscape of the Euromene countries in respect of national guidelines and recommendations for case definition, diagnosis and clinical approaches for ME/CFS patients. A 23 items questionnaire was sent out by email to the members of Euromene. The form contained questions on existing guidelines for case definitions, treatment/management of the disease, tests and questionnaires applied, and the prioritization of information for data sampling in research. We obtained information from 17 countries. Five countries reported having national guidelines for diagnosis, and five countries reported having guidelines for clinical approaches. For diagnostic purposes, the Fukuda criteria were most often recommended, and also the Canadian Consensus criteria, the International Consensus Criteria and the Oxford criteria were used. A mix of diagnostic criteria was applied within those countries having no guidelines. Many different questionnaires and tests were used for symptom registration and diagnostic investigation. For symptom relief, pain and anti-depressive medication were most often recommended. Cognitive Behavioral Therapy and Graded Exercise treatment were often recommended as disease management and rehabilitative/palliative strategies. The lack of consistency in recommendations across European countries urges the development of regulations, guidance and standards. The results of this study will contribute to the harmonization of diagnostic criteria and treatment for ME/CFS in Europe.
- Published
- 2019
8. Dental Care–Related Fear and Anxiety: Distress Tolerance as a Possible Mechanism
- Author
-
Addicks, S.H., primary, McNeil, D.W., additional, Randall, C.L., additional, Goddard, A., additional, Romito, L.M., additional, Sirbu, C., additional, Kaushal, G., additional, Metzger, A., additional, and Weaver, B.D., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Risk of relapse phenotype recurrence in multiple sclerosis
- Author
-
Kalincik, T, Buzzard, K, Jokubaitis, V, Trojano, M, Duquette, P, Izquierdo, G, Girard, M, Lugaresi, A, Grammond, P, Grand'Maison, F, Oreja-Guevara, C, Boz, C, Hupperts, R, Petersen, T, Giuliani, G, Iuliano, G, Lechner-Scott, J, Barnett, M, Bergamaschi, R, Van Pesch, V, Amato, MP, Van Munster, E, Fernandez-Bolanos, R, Verheul, F, Fiol, M, Cristiano, E, Slee, M, Rio, ME, Spitaleri, D, Alroughani, R, Gray, O, Saladino, ML, Flechter, S, Herbert, J, Cabrera-Gomez, JA, Vella, N, Paine, M, Shaw, C, Moore, F, Vucic, S, Savino, A, Singhal, B, Petkovska-Boskova, T, Parratt, J, Sirbu, C-A, Rozsa, C, Liew, D, Butzkueven, H, Kalincik, T, Buzzard, K, Jokubaitis, V, Trojano, M, Duquette, P, Izquierdo, G, Girard, M, Lugaresi, A, Grammond, P, Grand'Maison, F, Oreja-Guevara, C, Boz, C, Hupperts, R, Petersen, T, Giuliani, G, Iuliano, G, Lechner-Scott, J, Barnett, M, Bergamaschi, R, Van Pesch, V, Amato, MP, Van Munster, E, Fernandez-Bolanos, R, Verheul, F, Fiol, M, Cristiano, E, Slee, M, Rio, ME, Spitaleri, D, Alroughani, R, Gray, O, Saladino, ML, Flechter, S, Herbert, J, Cabrera-Gomez, JA, Vella, N, Paine, M, Shaw, C, Moore, F, Vucic, S, Savino, A, Singhal, B, Petkovska-Boskova, T, Parratt, J, Sirbu, C-A, Rozsa, C, Liew, D, and Butzkueven, H
- Abstract
OBJECTIVES: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of demographic and clinical features on this phenotype. METHODS: Information about relapses was collected using MSBase, an international observational registry. Associations between relapse phenotypes and history of similar relapses or patient characteristics were tested with multivariable logistic regression models. Tendency of relapse phenotypes to recur sequentially was assessed with principal component analysis. RESULTS: Among 14,969 eligible patients (89,949 patient-years), 49,279 phenotypically characterised relapses were recorded. Visual and brainstem relapses occurred more frequently in early disease and in younger patients. Sensory relapses were more frequent in early or non-progressive disease. Pyramidal, sphincter and cerebellar relapses were more common in older patients and in progressive disease. Women presented more often with sensory or visual symptoms. Men were more prone to pyramidal, brainstem and cerebellar relapses. Importantly, relapse phenotype was predicted by the phenotypes of previous relapses. (OR = 1.8-5, p = 10(-14)). Sensory, visual and brainstem relapses showed better recovery than other relapse phenotypes. Relapse severity increased and the ability to recover decreased with age or more advanced disease. CONCLUSION: Relapse phenotype was associated with demographic and clinical characteristics, with phenotypic recurrence significantly more common than expected by chance.
- Published
- 2014
10. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
- Author
-
Kalincik, T., Vivek, V., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Izquierdo, G., Lugaresi, A., Grand'Maison, F., Hupperts, R., Oreja-Guevara, C., Bergamaschi, R., Iuliano, G., Alroughani, R., van Pesch, V., Amato, M.P., Slee, M., Verheul, F., Fernandez-Bolanos, R., Fiol, M., Spitaleri, D.L., Cristiano, E., Gray, O., Cabrera-Gomez, J.A., Shaygannejad, V., Herbert, J., Vucic, S., Needham, M., Petkovska-Boskova, T., Sirbu, C-A, Duquette, P., Girard, M., Grammond, P., Boz, C., Giuliani, G., Rio, M.E., Barnett, M., Flechter, S., Moore, F., Singhal, B., Bacile, E.A., Saladino, M.L., Shaw, C., Skromne, E., Poehlau, D., Vella, N., Spelman, T., Liew, D., Kilpatrick, T.J., Butzkueven, H., Kalincik, T., Vivek, V., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Izquierdo, G., Lugaresi, A., Grand'Maison, F., Hupperts, R., Oreja-Guevara, C., Bergamaschi, R., Iuliano, G., Alroughani, R., van Pesch, V., Amato, M.P., Slee, M., Verheul, F., Fernandez-Bolanos, R., Fiol, M., Spitaleri, D.L., Cristiano, E., Gray, O., Cabrera-Gomez, J.A., Shaygannejad, V., Herbert, J., Vucic, S., Needham, M., Petkovska-Boskova, T., Sirbu, C-A, Duquette, P., Girard, M., Grammond, P., Boz, C., Giuliani, G., Rio, M.E., Barnett, M., Flechter, S., Moore, F., Singhal, B., Bacile, E.A., Saladino, M.L., Shaw, C., Skromne, E., Poehlau, D., Vella, N., Spelman, T., Liew, D., Kilpatrick, T.J., and Butzkueven, H.
- Abstract
The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship between sex and primary progressive disease course; and compare effects of age and disease duration on relapse incidence. Annualized relapse rates were calculated using the MSBase registry. Patients with incomplete data or <1 year of follow-up were excluded. Patients with primary progressive multiple sclerosis were only included in the sex ratio analysis. Relapse incidences over 40 years of multiple sclerosis or 70 years of age were compared between females and males with Andersen-Gill and Tweedie models. Female-to-male ratios stratified by annual relapse count were evaluated across disease duration and patient age and compared between relapse-onset and primary progressive multiple sclerosis. The study cohort consisted of 11 570 eligible patients with relapse-onset and 881 patients with primary progressive multiple sclerosis. Among the relapse-onset patients (82 552 patient-years), 48,362 relapses were recorded. Relapse frequency was 17.7% higher in females compared with males. Within the initial 5 years, the female-to-male ratio increased from 2.3:1 to 3.3:1 in patients with 0 versus ≥4 relapses per year, respectively. The magnitude of this sex effect increased at longer disease duration and older age (P < 10(-12)). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10(-12)). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.
- Published
- 2013
11. Relapse incidence in women and men throughout the course of multiple sclerosis: An MSBase cohort study
- Author
-
Kalincik, T., Vivek, V., Jokubaitis, V.G., Lechner-Scott, J., Trojano, M., Izquierdo, G., Lugaresi, A., Grand'Maison, F., Hupperts, R., Oreja-Guevara, C., Bergamaschi, R., Iuliano, G., Alroughani, R., van Pesch, V., Amato, M.P., Slee, M., Verheul, F., Fernandez-Bolanos, R., Fiol, M., Spitaleri, D., Cristiano, E., Gray, O., Cabrera-Gómez, J.A., Shaygannejad, V., Herbert, J., Vucic, S., Needham, M., Petkovska-Boskova, T., Adella Sirbu, C., Duquette, P., Girard, M., Grammond, P., Boz, C., Giuliani, G., Rio, M., Barnett, M.H., Flechter, S., Moore, F., Singhal, B., Bacie Bacile, E., Saladino, M., Shaw, C., Skromne, E., Vella, N., Spelman, T., Liew, D., Kilpatrick, T., Butzkueven, H., Kalincik, T., Vivek, V., Jokubaitis, V.G., Lechner-Scott, J., Trojano, M., Izquierdo, G., Lugaresi, A., Grand'Maison, F., Hupperts, R., Oreja-Guevara, C., Bergamaschi, R., Iuliano, G., Alroughani, R., van Pesch, V., Amato, M.P., Slee, M., Verheul, F., Fernandez-Bolanos, R., Fiol, M., Spitaleri, D., Cristiano, E., Gray, O., Cabrera-Gómez, J.A., Shaygannejad, V., Herbert, J., Vucic, S., Needham, M., Petkovska-Boskova, T., Adella Sirbu, C., Duquette, P., Girard, M., Grammond, P., Boz, C., Giuliani, G., Rio, M., Barnett, M.H., Flechter, S., Moore, F., Singhal, B., Bacie Bacile, E., Saladino, M., Shaw, C., Skromne, E., Vella, N., Spelman, T., Liew, D., Kilpatrick, T., and Butzkueven, H.
- Abstract
Introduction: Only one large retrospective cohort study and several smaller analyses examined predictors of relapse incidence in MS. Sex, age and MS duration were suggested as determinants of relapse activity. While in relapsing-remitting MS women are overrepresented in the ratio of 3:1 to men, in primary progressive disease both sexes are represented equally. A lower probability of relapse in men could be the reason for this change, with primary progressive (PP) MS representing the “extreme” of low relapse activity. Aims: To evaluate effect of sex on the incidence of MS relapses. To assess the hypothesis that the female-to-male ratio increases gradually with relapse activity and that PPMS represents a non-relapsing extreme along this continuum. To directly compare effects of age and MS duration on relapse incidence. Methods: Annualised relapse rates were calculated using the MSBase registry. Patients with incomplete data or less than one year of follow-up were excluded. Patients with PPMS were only included in the sex ratio analysis. Relapse incidences over 40 years of MS duration or up to 70 years of age were compared between females and males using Andersen-Gill and Poisson models. Female-to-male ratios stratified by annual relapse count were evaluated across disease duration and patient age and compared between relapse-onset and PPMS. All models were adjusted for therapy and pregnancy. Results: Among 11,570 eligible patients with relapse-onset MS (82,552 patient-years), 48,362 relapses were recorded. Relapse frequency was 17.7% higher in females compared to males. Within the initial five years, the female-to-male ratio increased from 2.3:1 to 3.3:1 in patients with 0 to >=4 relapses per year, respectively. The magnitude of this sex effect increased at longer MS duration and older age. However, the female-to-male ratio in patients with relapse-onset MS and zero relapses in any given year was double that of the patients with PPMS. Patient age was a more important
- Published
- 2013
12. Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors
- Author
-
Kalincik, T., Buzzard, K., Trojano, M., Duquette, P., Girard, M., Izquierdo, G., Grammond, P., Lugaresi, A., Petersen, T., Hupperts, R., Bergamaschi, R., Boz, C., Giuliani, G., Barnett, M.H., Lechner-Scott, J., Grand'Maison, F., Oreja-Guevara, C., Iuliano, G., Amato, M.P., Verheul, F., Cristiano, E., Fernandez-Bolanos, R., van Pesch, V., Fiol, M., Rio, M., Slee, M., Flechter, S., Gray, O., Saladino, M., Spitaleri, D., Cabrera-Gómez, J.A., Paine, M., Shaw, C., Alroughani, R., Vella, N., Rózsa, C., Vucic, S., Moore, F., Singhal, B., Deri, N., Needham, M., Santiago, V., Herbert, J., Savino, A., Adella Sirbu, C., Petkovska-Boskova, T., Bacile Bacile, E., Jokubaitis, V.G., Liew, D., Butzkueven, H., Kalincik, T., Buzzard, K., Trojano, M., Duquette, P., Girard, M., Izquierdo, G., Grammond, P., Lugaresi, A., Petersen, T., Hupperts, R., Bergamaschi, R., Boz, C., Giuliani, G., Barnett, M.H., Lechner-Scott, J., Grand'Maison, F., Oreja-Guevara, C., Iuliano, G., Amato, M.P., Verheul, F., Cristiano, E., Fernandez-Bolanos, R., van Pesch, V., Fiol, M., Rio, M., Slee, M., Flechter, S., Gray, O., Saladino, M., Spitaleri, D., Cabrera-Gómez, J.A., Paine, M., Shaw, C., Alroughani, R., Vella, N., Rózsa, C., Vucic, S., Moore, F., Singhal, B., Deri, N., Needham, M., Santiago, V., Herbert, J., Savino, A., Adella Sirbu, C., Petkovska-Boskova, T., Bacile Bacile, E., Jokubaitis, V.G., Liew, D., and Butzkueven, H.
- Abstract
Introduction: Our knowledge of incidence and outcomes of MS relapses with specific symptomatology is limited. For example, optic neuritis is more common in early MS and the ability to recover deteriorates with longer disease duration. However, a comprehensive evaluation of multiple sclerosis relapse phenotypes, comprising clinical presentations, severity, impact and recovery, and capturing full spectrum of MS courses, duration and patient demography, has not yet been done. Aim: To identify patterns of clinical MS relapses, their impact on specific neuroanatomical locations and their associations with demographic and clinical parameters. Methods: Information about relapse symptomatology was collected prospectively in 17,555 eligible patients and 104,333 patient-years recorded in MSBase, an international observational MS registry. In a proportion of the relapses, information about relapse severity, impact on activities of daily living and recovery was available. Associations between relapse phenotype and patient characteristics were tested with a series of multivariable logistic regression models. Principal component analysis was conducted to assess the tendency of the specific relapse locations to be involved sequentially in individual patients. Results: Of 63,343 relapses, the majority affected pyramidal and sensory functions. Visual and brainstem relapses occurred more frequently in early disease and in younger patients. Sensory relapses were recorded mostly in earlier disease and less commonly in relapsing-progressive disease. Pyramidal, sphincter and cerebellar relapses were more common in older patients and in progressive disease. Women more commonly presented with sensory or visual symptoms, while men were more prone to pyramidal, brainstem and cerebellar relapses. Relapses were likely to recur within the previously affected locations (odd ratios 1.8 – 5, p = 10^-13), with pyramidal, sphincter and sensory relapses often converging within the same individuals (e
- Published
- 2013
13. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
- Author
-
Kalincik, T, Vivek, V, Jokubaitis, V, Lechner-Scott, J, Trojano, M, Izquierdo, G, Lugaresi, A, Grand'Maison, F, Hupperts, R, Oreja-Guevara, C, Bergamaschi, R, Iuliano, G, Alroughani, R, Van Pesch, V, Amato, MP, Slee, M, Verheul, F, Fernandez-Bolanos, R, Fiol, M, La Spitaleri, D, Cristiano, E, Gray, O, Antonio Cabrera-Gomez, J, Shaygannejad, V, Herbert, J, Vucic, S, Needham, M, Petkovska-Boskova, T, Sirbu, C-A, Duquette, P, Girard, M, Grammond, P, Boz, C, Giuliani, G, Rio, ME, Barnett, M, Flechter, S, Moore, F, Singhal, B, Alejandra Bacile, E, Laura Saladino, M, Shaw, C, Skromne, E, Poehlau, D, Vella, N, Spelman, T, Liew, D, Kilpatrick, TJ, Butzkueven, H, Kalincik, T, Vivek, V, Jokubaitis, V, Lechner-Scott, J, Trojano, M, Izquierdo, G, Lugaresi, A, Grand'Maison, F, Hupperts, R, Oreja-Guevara, C, Bergamaschi, R, Iuliano, G, Alroughani, R, Van Pesch, V, Amato, MP, Slee, M, Verheul, F, Fernandez-Bolanos, R, Fiol, M, La Spitaleri, D, Cristiano, E, Gray, O, Antonio Cabrera-Gomez, J, Shaygannejad, V, Herbert, J, Vucic, S, Needham, M, Petkovska-Boskova, T, Sirbu, C-A, Duquette, P, Girard, M, Grammond, P, Boz, C, Giuliani, G, Rio, ME, Barnett, M, Flechter, S, Moore, F, Singhal, B, Alejandra Bacile, E, Laura Saladino, M, Shaw, C, Skromne, E, Poehlau, D, Vella, N, Spelman, T, Liew, D, Kilpatrick, TJ, and Butzkueven, H
- Abstract
The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship between sex and primary progressive disease course; and compare effects of age and disease duration on relapse incidence. Annualized relapse rates were calculated using the MSBase registry. Patients with incomplete data or <1 year of follow-up were excluded. Patients with primary progressive multiple sclerosis were only included in the sex ratio analysis. Relapse incidences over 40 years of multiple sclerosis or 70 years of age were compared between females and males with Andersen-Gill and Tweedie models. Female-to-male ratios stratified by annual relapse count were evaluated across disease duration and patient age and compared between relapse-onset and primary progressive multiple sclerosis. The study cohort consisted of 11 570 eligible patients with relapse-onset and 881 patients with primary progressive multiple sclerosis. Among the relapse-onset patients (82 552 patient-years), 48,362 relapses were recorded. Relapse frequency was 17.7% higher in females compared with males. Within the initial 5 years, the female-to-male ratio increased from 2.3:1 to 3.3:1 in patients with 0 versus ≥4 relapses per year, respectively. The magnitude of this sex effect increased at longer disease duration and older age (P < 10(-12)). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10(-12)). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.
- Published
- 2013
14. Does Advanced Age Affect the Anticoagulation Protocols or Outcomes?.
- Author
-
Zarrouf, FA, primary, Ibrahim, S, additional, Sirbu, C, additional, and Griffith, JP, additional
- Published
- 2009
- Full Text
- View/download PDF
15. The potential clinical role of ultrasonic strain and strain rate imaging in diagnosing acute rejection after heart transplantation☆
- Author
-
MARCINIAK, A, primary, EROGLU, E, additional, MARCINIAK, M, additional, SIRBU, C, additional, HERBOTS, L, additional, DROOGNE, W, additional, CLAUS, P, additional, DHOOGE, J, additional, BIJNENS, B, additional, and VANHAECKE, J, additional
- Published
- 2007
- Full Text
- View/download PDF
16. 300 The assessment of left ventricular wall radial and circumferential deformation in biatrial and bicaval heart transplanted patients A 2D strain ultrasonic imaging study
- Author
-
SIRBU, C, primary, SHEBANI, S, additional, DHOOGE, J, additional, CLAUS, P, additional, MATTEI, M, additional, VILLEMOT, J, additional, and RADEMAKERS, F, additional
- Published
- 2006
- Full Text
- View/download PDF
17. Feasibility of strain and strain rate imaging for the assessment of regional left atrial deformation: A study in normal subjects
- Author
-
SIRBU, C, primary, HERBOTS, L, additional, DHOOGE, J, additional, CLAUS, P, additional, MARCINIAK, A, additional, LANGELAND, T, additional, BIJNENS, B, additional, RADEMAKERS, F, additional, and SUTHERLAND, G, additional
- Published
- 2006
- Full Text
- View/download PDF
18. Fluoride release from dental resin composites
- Author
-
Furtos, G., primary, Cosma, V., additional, Prejmerean, C., additional, Moldovan, M., additional, Brie, M., additional, Colceriu, A., additional, Vezsenyi, L., additional, Silaghi-Dumitrescu, L., additional, and Sirbu, C., additional
- Published
- 2005
- Full Text
- View/download PDF
19. Spinal anesthesia for ambulatory urologic surgery: mini-dose lidocaine versus mini-dose bupivacaine versus conventional dose bupivacaine
- Author
-
Sandesc, D., primary, Lupei, M. I., additional, Sirbu, C., additional, and Plavat, C., additional
- Published
- 2004
- Full Text
- View/download PDF
20. BIOPOLYMERS FROM LEATHER WASTE APPLIED IN AGRICULTURE.
- Author
-
Zainescu, G., Deselnicu, D., Ioannidis, I., Constantinescu, R., Voicu, P., and Sirbu, C.
- Subjects
BIOPOLYMERS ,INDUSTRIAL wastes ,POLYELECTROLYTES ,SOLID waste ,WASTE products ,BIODEGRADABLE products - Abstract
Many industries, including leather industry, are faced with high expenditure for solid organic waste treatment and disposal.Organic biopolymers represent a source of raw material for agriculture, because the composition of protean wastes provides enough elements to improve composition and rehabilitation of degraded soils.The main target of this scientific paper is investigating the development possibilities for various multicompound systems of biodegradable polymers and studying the effects of these complex products on the structure and chemical and physical characteristics of degraded or contaminated soils (having a poor level of organic matter or submitted to a strong erosion process). All treatments applied to wastes aim at substantially reducing environmental pollution. Complex characteristics of protean wastes from the leather industry are approached by accurately determining waste hide chemical composition and various possibilities of recovery and recycling using biotechnologies The novelty resides in the theoretically-based practical indications regarding the rational application of complex polymeric products - biofertilizers - on various types of soil (sandy, salty, eroded, dumps etc.) depending on the requirements of soil remediation and nutrition specific to agricultural plants. The work presents a new pilot technology for biochemical decay of the tannery protein wastes and use of the resulted products as fertilizers. [ABSTRACT FROM AUTHOR]
- Published
- 2013
21. European Law within the Tax Evasion Area.
- Author
-
Ariton, D. B., Nuta, A., Nuta, F., Sirbu, C., Raileanu, A., and Ariton, D. A.
- Subjects
TAX evasion ,FISCAL policy ,FINANCIAL management - Abstract
This article present the tax evasion problems in European Union framework, Union that must be equilibrium state among other tow concepts: fiscal harmonisation and fiscal competition. The measures that are justified to be taken in the name of harmonization may be considered as obstacles for the fiscal competition among member state and can conduce to the tax evasion. [ABSTRACT FROM AUTHOR]
- Published
- 2010
22. Testosterone and depression: systematic review and meta-analysis.
- Author
-
Zarrouf FA, Artz S, Griffith J, Sirbu C, and Kommor M
- Published
- 2009
- Full Text
- View/download PDF
23. Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms.
- Author
-
Smith RC, Gardiner JC, Lyles JS, Sirbu C, Dwamena FC, Hodges A, Collins C, Lein C, Given CW, Given B, Goddeeris J, Smith, Robert C, Gardiner, Joseph C, Lyles, Judith S, Sirbu, Corina, Dwamena, Francesca C, Hodges, Annemarie, Collins, Clare, Lein, Catherine, and Given, C William
- Published
- 2005
- Full Text
- View/download PDF
24. Dysembryoplastic Neuroepithelial Tumor With Probable Sudden Unexplained Death In Epilepsy.
- Author
-
Sirbu, C. A.
- Subjects
- *
SUDDEN death , *SEIZURES (Medicine) , *NEUROPSYCHOLOGY , *BRAIN diseases , *EPILEPSY , *CAUSES of death - Abstract
A patient with a natural history of dysembryoblastic neuroepitelial tumor (DNT) with associated with probable sudden unexplained death (SUDEP) is described. This patient had long period of intractable partial complex seizures, neuropsychological abnormalities and normal neurological examination. [ABSTRACT FROM AUTHOR]
- Published
- 2011
25. Expectations and realities of Romanian European integration of Romanian SME sector
- Author
-
Ariton, D., Sirbu, C. G., Nuta, A. C., Alina Beatrice Raileanu, and Nuta, F. M.
26. From pathophysiology to molecular diagnosis in sudden unexpected death in epilepsy
- Author
-
Sirbu, C. -A, Corneci, D., Plesa, F. -C, Sirbu, O. -M, Sandu, A. -M, and Ioan, B.
27. Can we really prevent Alzheimer’s disease?
- Author
-
Sirbu, O. -M, Sandu, A. -M, Plesa, F. -C, and Sirbu, C. -A
28. Predictors of Confirmed Disability Progression after a First Demyelinating Event
- Author
-
Butzkueven, H., Spelman, T., Izquierdo, G., Grand-Maison, F., Trojano, M., Zwanikken, C., Oreja-Guevara, C., Lugaresi, A., Petersen, T., Boz, C., Grammond, P., Iuliano, G., Duquette, P., Girard, M., Fiol, M., Gomez, J. C., Hupperts, R., Giuliani, G., Lechner-Scott, J., Verheul, F., Bergamaschi, R., Cristiano, E., Pesch, V., Saladino, M., Herbert, J., Petkovska-Boskova, T., Vella, N., Moore, F., Mark Slee, Havrdova, E., Paine, M., Young, C., Shaw, C., Barnett, M., and Sirbu, C.
29. Neuroimunotoxicity of aluminum
- Author
-
Sirbu, C. A., Sirbu, O. M., Constantin, C., and Sandu, A.
30. Chronic progressive external ophtalmoplegia (CPEO) – Case presentation
- Author
-
Sirbu, C. -A, Sirbu, O. -M, and Sandu, A. -M
31. Treatment of Mitral Valve Regurgitation with an Open Rigid Annuloplasty Ring
- Author
-
Venner, C., Huttin, O., Antonio Fiore, Sirbu, C., Villemot, J. -P, and Maureira, J. -P
- Subjects
n/a
32. Poster session 2: Thursday 4 December 2014, 08:30-12:30 * Location: Poster area
- Author
-
Domingos, JS, Augustine, DX, Leeson, P, Noble, JA, Doan, H-L, Boubrit, L, Cheikh-Khalifa, R, Laveau, F, Djebbar, M, Pousset, F, Isnard, R, Hammoudi, N, Lisi, M, Cameli, M, Di Tommaso, C, Curci, V, Reccia, R, Maccherini, M, Henein, M Y, Mondillo, S, Leitman, M, Vered, Z, Rashid, H, Yalcin, M U, Gurses, K M, Kocyigit, D, Evranos, B, Yorgun, H, Sahiner, L, Kaya, B, Aytemir, K, Ozer, N, Bertella, E, Petulla', M, Baggiano, A, Mushtaq, S, Russo, E, Gripari, P, Innocenti, E, Andreini, D, Tondo, C, Pontone, G, Necas, J, Kovalova, S, Hristova, K, Shiue, I, Bogdanva, V, Teixido Tura, G, Sanchez, V, Rodriguez-Palomares, J, Gutierrez, L, Gonzalez-Alujas, T, Garcia-Dorado, D, Forteza, A, Evangelista, A, Timoteo, A T, Aguiar Rosa, S, Cruz Ferreira, R, Campbell, R, Carrick, D, Mccombe, C, Tzemos, N, Berry, C, Sonecki, P, Noda, M, Setoguchi, M, Ikenouchi, T, Nakamura, T, Yamamoto, Y, Murakami, T, Katou, Y, Usui, M, Ichikawa, K, Isobe, M, Kwon, BJ, Roh, JW, Kim, HY, Ihm, SH, Barron, A J, Francis, DP, Mayet, J, Wensel, R, Kosiuk, J, Dinov, B, Bollmann, A, Hindricks, G, Breithardt, OA, Rio, P, Moura Branco, L, Galrinho, A, Cacela, D, Pinto Teixeira, P, Afonso Nogueira, M, Pereira-Da-Silva, T, Abreu, J, Teresa Timoteo, A, Cruz Ferreira, R, Pavlyukova, EN, Tereshenkova, EK, Karpov, RS, Piatkowski, R, Kochanowski, J, Opolski, G, Barbier, P, Mirea, O, Guglielmo, M, Savioli, G, Cefalu, C, Pudil, R, Horakova, L, Rozloznik, M, Balestra, C, P37/03, PRVOUK, Rimbas, RC, Enescu, OA, Calin, S, Vinereanu, D, POSDRU/159/1.5/S/141531, Grant, Karsenty, C, Hascoet, S, Hadeed, K, Semet, F, Dulac, Y, Alacoque, X, Leobon, B, Acar, P, Dharma, S, Sukmawan, R, Soesanto, AM, Vebiona, KPP, Firdaus, I, Danny, SS, Driessen, M M P, Sieswerda, GTJ, Post, MC, Snijder, RJ, Van Dijk, APJ, Leiner, T, Meijboom, FJ, Chrysohoou, C, Tsitsinakis, G, Tsiachris, D, Aggelis, A, Herouvim, E, Vogiatzis, I, Pitsavos, C, Koulouris, G, Stefanadis, C, Erdei, T, Edwards, J, Braim, D, Yousef, Z, Fraser, AG, Cardiff, Investigators, MEDIA, Avenatti, E, Magnino, C, Omede', P, Presutti, D, Moretti, C, Iannaccone, A, Ravera, A, Gaita, F, Milan, A, Veglio, F, Barbier, P, Scali, MC, Simioniuc, A, Guglielmo, M, Savioli, G, Cefalu, C, Mirea, O, Fusini, L, Dini, F, Okura, H, Murata, E, Kataoka, T, Mikaelpoor, A, Ojaghi Haghighi, SH, Ojaghi Haghighi, SZ, Alizadeasl, A, Sharifi-Zarchi, A, Zaroui, A, Ben Halima, M, Mourali, MS, Mechmeche, R, Rodriguez Palomares, J F, Gutierrez, LG, Maldonado, GM, Garcia, GG, Otaegui, IO, Garcia Del Blanco, BGB, Teixido, GT, Gonzalez Alujas, MTGA, Evangelista, AE, Garcia Dorado, DGD, Godinho, A R, Correia, AS, Rangel, I, Rocha, A, Rodrigues, J, Araujo, V, Almeida, PB, Macedo, F, Maciel, MJ, Rekik, B, Mghaieth, F, Aloui, H, Boudiche, S, Jomaa, M, Ayari, J, Tabebi, N, Farhati, A, Mourali, S, Dekleva, M, Markovic-Nikolic, N, Zivkovic, M, Stankovic, A, Boljevic, D, Korac, N, Beleslin, B, Arandjelovic, A, Ostojic, M, Galli, E, Guirette, Y, Auffret, V, Daudin, M, Fournet, M, Mabo, P, Donal, E, Chin, C W L, Luo, E, Hwan, J, White, A, Newby, D, Dweck, M, Carstensen, H G, Larsen, L H, Hassager, C, Kofoed, K F, Jensen, J S, Mogelvang, R, Kowalczyk, M, Debska, M, Kolesnik, A, Dangel, J, Kawalec, W, Migliore, RA, Adaniya, ME, Barranco, MA, Miramont, G, Gonzalez, S, Tamagusuku, H, Davidsen, E S, Kuiper, K K J, Matre, K, Gerdts, E, Igual Munoz, B, Maceira Gonzalez, AMG, Erdociain Perales, MEP, Estornell Erill, JEE, Valera Martinez, FVM, Miro Palau, VMP, Piquer Gil, MPG, Sepulveda Sanchez, PSS, Cervera Zamora, ACZ, Montero Argudo, AMA, Placido, R, Silva Marques, J, Magalhaes, A, Guimaraes, T, Nobre E Menezes, M, Goncalves, S, Ramalho, A, Robalo Martins, S, Almeida, AG, Nunes Diogo, A, Abid, L, Ben Kahla, S, Charfeddine, S, Abid, D, Kammoun, S, Tounsi, A, Abid, LEILA, Abid, DORRA, Charfeddine, SALMA, Hammami, RANIA, Triki, FETEN, Akrout, MALEK, Mallek, SOUAD, Hentati, MOURAD, Kammoun, SAMIR, Sirbu, C F, Berrebi, A, Huber, A, Folliguet, T, Yang, L-T, Shih, JY, Liu, YW, Li, YH, Tsai, LM, Luo, CY, Tsai, WC, Babukov, R, Bartosh, F, Bazilev, V, Muraru, D, Cavalli, G, Addetia, K, Miglioranza, MH, Veronesi, F, Mihaila, S, Tadic, M, Cucchini, U, Badano, L, Lang, RM, Miyazaki, S, Slavich, M, Miyazaki, T, Figini, F, Lativ, A, Chieffo, A, Montrfano, M, Alfieri, O, Colombo, A, Agricola, E, Liu, D, Hu, K, Herrmann, S, Stoerk, S, Kramer, B, Ertl, G, Bijnens, B, Weidemann, F, Brand, M, Butz, T, Tzikas, S, Van Bracht, M, Roeing, J, Wennemann, R, Christ, M, Grett, M, Trappe, H-J, Scherzer, S, Geroldinger, AG, Krenn, L, Roth, C, Gangl, C, Maurer, G, Rosenhek, R, Neunteufl, T, Binder, T, Bergler-Klein, J, Martins, E, Pinho, T, Leite, S, Azevedo, O, Belo, A, Campelo, M, Amorim, S, Rocha-Goncalves, F, Goncalves, L, Silva-Cardoso, J, Ahn, HS, Kim, KT, Jeon, HK, Youn, HJ, Haland, T, Saberniak, J, Leren, IS, Edvardsen, T, Haugaa, KH, Ziolkowska, L, Boruc, A, Kowalczyk, M, Turska-Kmiec, A, Zubrzycka, M, Kawalec, W, Monivas Palomero, V, Mingo Santos, S, Goirigolzarri Artaza, J, Rodriguez Gonzalez, E, Rivero Arribas, B, Castro Urda, V, Dominguez Rodriguez, F, Mitroi, C, Gracia Lunar, I, Fernadez Lozano, I, Palecek, T, Masek, M, Kuchynka, P, Fikrle, M, Spicka, I, Rysava, R, Linhart, A, Saberniak, J, Hasselberg, NE, Leren, IS, Haland, T, Borgquist, R, Platonov, PG, Edvardsen, T, Haugaa, KH, Ancona, R, Comenale Pinto, S, Caso, P, Coopola, MG, Arenga, F, Rapisarda, O, D'onofrio, A, Sellitto, V, Calabro, R, Rosca, M, Popescu, BA, Calin, A, Mateescu, A, Beladan, CC, Jalba, M, Rusu, E, Zilisteanu, D, Ginghina, C, Pressman, G, Cepeda-Valery, B, Romero-Corral, A, Moldovan, R, Saenz, A, Orban, M, Samuel, SP, Fijalkowski, M, Fijalkowska, M, Gilis-Siek, N, Blaut, K, Galaska, R, Sworczak, K, Gruchala, M, Fijalkowski, M, Nowak, R, Gilis-Siek, N, Fijalkowska, M, Galaska, R, Gruchala, M, Ikonomidis, I, Triantafyllidi, H, Trivilou, P, Tzortzis, S, Papadopoulos, C, Pavlidis, G, Paraskevaidis, I, Lekakis, J, Padiyath, A, Li, L, Xiao, Y, Danford, DA, Kutty, S, Kaymaz, C, Aktemur, T, Poci, N, Ozturk, S, Akbal, O, Yilmaz, F, Tokgoz Demircan, HC, Kirca, N, Tanboga, IH, Ozdemir, N, Investigators, EUPHRATES, Greiner, S, Jud, A, Aurich, M, Hess, A, Hilbel, T, Hardt, S, Katus, HA, D'ascenzi, F, Cameli, M, Alvino, F, Lisi, M, Focardi, M, Solari, M, Bonifazi, M, Mondillo, S, Konopka, M, Krol, W, Klusiewicz, A, Burkhard, K, Chwalbinska, J, Pokrywka, A, Dluzniewski, M, Braksator, W, King, G J, Coen, K, Gannon, S, Fahy, N, Kindler, H, Clarke, J, Iliuta, L, Rac-Albu, M, Placido, R, Robalo Martins, S, Guimaraes, T, Nobre E Menezes, M, Cortez-Dias, N, Francisco, A, Silva, G, Goncalves, S, Almeida, AG, Nunes Diogo, A, Kyu, K, Kong, WKF, Songco, GG, Galupo, MJ, Castro, MD, Shin Hnin, W, Ronald Lee, CH, Poh, KK, Milazzo, V, Di Stefano, C, Tosello, F, Leone, D, Ravera, A, Sabia, L, Sobrero, G, Maule, S, Veglio, F, Milan, A, Jamiel, A M, Ahmed, A M, Farah, I, Al-Mallah, M H, Petroni, R, Magnano, R, Bencivenga, S, Di Mauro, M, Petroni, S, Altorio, SF, Romano, S, Penco, M, Kumor, M, Lipczynska, M, Klisiewicz, A, Wojcik, A, Konka, M, Kozuch, K, Szymanski, P, Hoffman, P, Rimbas, RC, Rimbas, M, Enescu, OA, Mihaila, S, Calin, S, Vinereanu, D, 112/2011, Grant CNCSIS, 159/1.5/S/141531, Grant POSDRU, Donal, E, Reynaud, A, Lund, LH, Persson, H, Hage, C, Oger, E, Linde, C, Daubert, JC, investigators, KaRen, Maria Oliveira Lima, M, Costa, H, Gomes Da Silva, M, Noman Alencar, MC, Carmo Pereira Nunes, M, Costa Rocha, MO, Abid, L, Charfeddine, S, Ben Kahla, S, Abid, D, Siala, A, Hentati, M, Kammoun, S, Kovalova, S, Necas, J, Ozawa, K, Funabashi, N, Takaoka, H, Kobayashi, Y, Matsumura, Y, Wada, M, Hirakawa, D, Yasuoka, Y, Morimoto, N, Takeuchi, H, Kitaoka, H, Sugiura, T, Lakkas, L, Naka, KK, Ntounousi, E, Gkirdis, I, Koutlas, V, Bechlioulis, A, Pappas, K, Katsouras, CS, Siamopoulos, K, Michalis, LK, Naka, KK, Evangelou, D, Kalaitzidis, R, Bechlioulis, A, Lakkas, L, Gkirdis, I, Tzeltzes, G, Nakas, G, Katsouras, CS, Michalis, LK, Generati, G, Bandera, F, Pellegrino, M, Labate, V, Alfonzetti, E, Guazzi, M, Zagatina, A, Zhuravskaya, N, Al-Mallah, M, Alsaileek, A, Qureshi, W, Karsenty, C, Hascoet, S, Peyre, M, Hadeed, K, Alacoque, X, Amadieu, R, Leobon, B, Dulac, Y, Acar, P, Yamanaka, Y, Sotomi, Y, Iwakura, K, Inoue, K, Toyoshima, Y, Tanaka, K, Oka, T, Tanaka, N, Orihara, Y, Fujii, K, Soulat-Dufour, L, Lang, S, Boyer-Chatenet, L, Van Der Vynckt, C, Ederhy, S, Adavane, S, Haddour, N, Boccara, F, Cohen, A, Huitema, MP, Boerman, S, Vorselaars, VMM, Grutters, JC, Post, MC, Gopal, A S, Saha, SK, Toole, RS, Kiotsekoglou, A, Cao, JJ, Reichek, N, Meyer, C G, Altiok, E, Al Ateah, G, Lehrke, M, Becker, M, Lotfi, S, Autschbach, R, Marx, N, Hoffmann, R, Frick, M, Nemes, A, Sepp, R, Kalapos, A, Domsik, P, Forster, T, Caro Codon, J, Blazquez Bermejo, Z, Lopez Fernandez, T, Valbuena Lopez, S C, Iniesta Manjavacas, A M, De Torres Alba, F, Dominguez Melcon, F, Pena Conde, L, Moreno Yanguela, M, Lopez-Sendon, J L, Nemes, A, Lengyel, C, Domsik, P, Kalapos, A, Orosz, A, Varkonyi, TT, Forster, T, Rendon, J, Saldarriaga, C I, Duarte, N, Nemes, A, Domsik, P, Kalapos, A, Forster, T, Nemes, A, Domsik, P, Kalapos, A, Sepp, R, Foldeak, D, Borbenyi, Z, Forster, T, Hamdy, AM, Fereig, HM, Nabih, MA, Abdel-Aziz, A, Ali, AA, Broyd, CJ, Wielandts, J-Y, De Buck, S, Michielsen, K, Louw, R, Garweg, C, Nuyts, J, Ector, J, Maes, F, Heidbuchel, H, Gillis, K, Bala, G, Tierens, S, Cosyns, B, Maurovich-Horvat, P, Horvath, T, Jermendy, A, Celeng, C, Panajotu, A, Bartykowszki, A, Karolyi, M, Tarnoki, AD, Jermendy, G, and Merkely, B
- Abstract
Purpose: 3D echocardiography (3DE) enables fast 3D acquisition but subsequent manual navigation to find 2D diagnostic planes can be time consuming. We have developed and validated an automated machine learning-based technique to find apical 2-, 3- and 4-chamber (A2C, A3C, A4C) views that enables fast volume navigation and analysis. Methods: 3DE volumes were acquired (Philips iE33: X3-1 and X5-1 probes) from 30 healthy volunteers and 36 clinical patients with suspected valve disease and coronary heart disease. 66 end diastolic volumes were used to assess the accuracy of apical standard view finding by our method against manual plane finding. To do this, dedicated software was developed with a machine learning approach and a 3-fold cross validation of results was performed. Results: Automatic A4C view detection was possible in 60/66 (91%) of volumes; detection failures were due to suboptimal myocardium wall integrity or lack of right ventricle in the scan. A2C and A3C views were extracted from the A4C view using the known geometrical relationships between apical standard views (A2C to A3C: 30°~40° and A2C to A4C: 90° of rotation over the left ventricle long axis, as shown in the Figure). In average, our method accurately found the heart apex and mitral valve centre with a 7.1 ± 5.7 mm and 7.2 ± 5.3 mm error, respectively. Conclusions: In order to automate clinical workflow, we have developed a new and fully automatic machine learning strategy for apical standard view finding which performed well (91% detection accuracy) on volunteer and clinical 3D echocardiograms.
Figure - Published
- 2014
- Full Text
- View/download PDF
33. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype
- Author
-
Riadh Gouider, Talal Al-Harbi, Krisztian Kasa, Ingrid van der Mei, Carmen Adella Sirbu, Richard Roxburgh, Alessandra Lugaresi, Daniele Spitaleri, Karim Kotkata, Steve Simpson, Javier Olascoaga, Edgardo Cristiano, Raed Alroughani, Tomas Kalincik, Cameron Shaw, Attila Sas, Bruce V. Taylor, Jim Stankovich, Ayse Altintas, Bassem Yamout, Yuan Zhou, Suzi B. Claflin, José C. Álvarez-Cermeño, Tünde Csépány, José Luis Sánchez Menoyo, Guy Laureys, Danny Decoo, Helmut Butzkueven, Seyed Aidin Sajedi, Leigh Blizzard, Franco Granella, Christopher McGuigan, Yara Dadalti Fragoso, Jorge Millán-Pascual, Eugenio Pucci, Allan G. Kermode, Todd A. Hardy, Stella Hughes, Zhou Y., Claflin S.B., Stankovich J., van der Mei I., Simpson S., Roxburgh R.H., Kalincik T., Blizzard L., Lugaresi A., Alroughani R., Sajedi S.A., Butzkueven H., Pucci E., Spitaleri D.L.A., Granella F., Cristiano E., Yamout B., Hughes S., Gouider R., Sanchez Menoyo J.L., Olascoaga J., McGuigan C., Shaw C., Kermode A.G., Kasa K., Al-Harbi T., Altintas A., Laureys G., Fragoso Y., Hardy T.A., Csepany T., Sirbu C.-A., Decoo D., Sas A., Alvarez-Cermeno J.C., Kotkata K., Millan-Pascual J., and Taylor B.V.
- Subjects
Male ,medicine.medical_specialty ,Multiple Sclerosis ,Severity of Illness Index ,Disability Evaluation ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Internal medicine ,medicine ,Humans ,Disability progression ,Multiple sclerosi ,030304 developmental biology ,0303 health sciences ,business.industry ,Multiple sclerosis ,onset phenotype ,medicine.disease ,Phenotype ,Clinical neurology ,disability progression ,Neurology ,Disease Progression ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Multiple Sclerosis Severity Score - Abstract
Background: The Multiple Sclerosis Severity Score (MSSS) is a widely used measure of the disability progression rate. However, the global MSSS may not be the best basis for comparison between all patient groups. Objective: We evaluated sex-specific and onset phenotype–specific MSSS matrices to determine if they were more effective than the global MSSS as a basis for comparison within these subsets. Methods: Using a large international dataset of multiple sclerosis (MS) patient records and the original MSSS algorithm, we constructed global, sex-specific and onset phenotype–specific MSSS matrices. We compared matrices using permutation analysis. Results: Our final dataset included 30,203 MS cases, with 28.9% males and 6.5% progressive-onset cases. Our global MSSS matrix did not differ from previously published data ( p > 0.05). The progressive-onset-specific matrix differed significantly from the relapsing-onset-specific matrix ( p Conclusion: The differences in the disability accrual rate between progressive- and relapsing-onset MS have a significant effect on MSSS. An onset-specific MSSS should be used when comparing the rate of disability progression among progressive-onset cases and for mixed cohorts.
- Published
- 2020
34. Delay from treatment start to full effect of immunotherapies for multiple sclerosis
- Author
-
Roos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Brown, J William L, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Bergamaschi, Roberto, Sá, Maria José, Cartechini, Elisabetta, Boz, Cavit, Granella, Franco, Hupperts, Raymond, Terzi, Murat, Lechner-Scott, Jeannette, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Olascoaga, Javier, Prevost, Julie, Aguera-Morales, Eduardo, Slee, Mark, Csepany, Tunde, Turkoglu, Recai, Sidhom, Youssef, Gouider, Riadh, Van Wijmeersch, Bart, McCombe, Pamela, Macdonell, Richard, Coles, Alasdair, Malpas, Charles, Butzkueven, Helmut, Vukusic, Sandra, Kalincik, Tomas, Duquette, Pierre, Grand'Maison, Francois, Iuliano, Gerardo, Ramo-Tello, Cristina, Solaro, Claudio, Cabrera-Gomez, Jose Antonio, Rio, Maria Edite, Bolaños, Ricardo Fernandez, Shaygannejad, Vahid, Oreja-Guevara, Celia, Sanchez-Menoyo, Jose Luis, Petersen, Thor, Altintas, Ayse, Barnett, Michael, Flechter, Shlomo, Fragoso, Yara, Amato, Maria Pia, Moore, Fraser, Ampapa, Radek, Verheul, Freek, Hodgkinson, Suzanne, Cristiano, Edgardo, Yamout, Bassem, Laureys, Guy, Dominguez, Jose Andres, Zwanikken, Cees, Deri, Norma, Dobos, Eniko, Vrech, Carlos, Butler, Ernest, Rozsa, Csilla, Petkovska-Boskova, Tatjana, Karabudak, Rana, Rajda, Cecilia, Alkhaboori, Jabir, Saladino, Maria Laura, Shaw, Cameron, Shuey, Neil, Vucic, Steve, Sempere, Angel Perez, Campbell, Jamie, Piroska, Imre, Taylor, Bruce, van der Walt, Anneke, Kappos, Ludwig, Roullet, Etienne, Gray, Orla, Simo, Magdolna, Sirbu, Carmen-Adella, Brochet, Bruno, Cotton, François, De Sèze, Jérôme, Dion, Armelle, Douek, Pascal, Guillemin, Francis, Laplaud, David, Lebrun-Frenay, Christine, Moreau, Thibault, Olaiz, Javier, Pelletier, Jean, Rigaud-Bully, Claire, Stankoff, Bruno, Marignier, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Collongues, Nicolas, Lubetzki, Catherine, Vermersch, Patrick, Labauge, Pierre, Defer, Gilles, Cohen, Mikaël, Fromont, Agnès, Wiertlewsky, Sandrine, Berger, Eric, Clavelou, Pierre, Audoin, Bertrand, Giannesini, Claire, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Créange, Alain, Camdessanché, Jean-Philippe, Faure, Justine, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, University of Melbourne, The Royal Melbourne Hospital, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Swinburne University of Technology [Melbourne], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, University of Cambridge [UK] (CAM), Medicine Charles University and General Faculty Hospital in Prague, University of Bari Aldo Moro (UNIBA), University of Catania [Italy], Hospital Universitario Virgen Macarena [Seville, Spain], University 'G. d'Annunzio' of Chieti-Pescara [Chieti], Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Université de Montréal (UdeM), University of Modena and Reggio Emilia, Partenaires INRAE, Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] (DEÜ), IRCCS Mondino Foundation, Universidade Fernando Pessoa, KTU Medical Faculty Farabi Hospital, University of Parma = Università degli studi di Parma [Parme, Italie], Zuyderland Ziekenhuis, Medical Faculty [Samsun, Turkey], University of Newcastle [Australia] (UoN), Université Catholique de Louvain = Catholic University of Louvain (UCL), Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Hospital Universitario Donostia, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Haydarpasa Numune Training and Research Hospital, Hasselt University (UHasselt), University of Queensland [Brisbane], Hitachi Cambridge Laboratory [University of Cambridge], Hitachi, Ltd-University of Cambridge [UK] (CAM), Monash University [Melbourne], Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Ospedali Riuniti di Salerno, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), 1157717, National Health and Medical Research Council, Biogen, MSIF-ARSEP McDonald, Melbourne Research Scholarship, French State, ‘Agence Nationale de la Recherche,’, ANR-10-COHO-002, ‘Investments for the Future’, Eugène Devic EDMUS Foundation, ARSEP Foundation, Novartis, Merck, Roche, Teva Pharmaceutical Industries, Sanofi Genzyme, EDMUS Foundation, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Roos I., Leray E., Frascoli F., Casey R., Brown W.J.L., Horakova D., Havrdova E.K., Trojano M., Patti F., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., Prat A., Girard M., Grammond P., Sola P., Ferraro D., Ozakbas S., Bergamaschi R., Sa M.J., Cartechini E., Boz C., Granella F., Hupperts R., Terzi M., Lechner-Scott J., Spitaleri D., van Pesch V., Soysal A., Olascoaga J., Prevost J., Aguera-Morales E., Slee M., Csepany T., Turkoglu R., Sidhom Y., Gouider R., van Wijmeersch B., McCombe P., Macdonell R., Coles A., Malpas C.B., Butzkueven H., Vukusic S., Kalincik T., Duquette P., Grand'Maison F., Iuliano G., Ramo-Tello C., Solaro C., Cabrera-Gomez J.A., Rio M.E., Bolanos R.F., Shaygannejad V., Oreja-Guevara C., Sanchez-Menoyo J.L., Petersen T., Altintas A., Barnett M., Flechter S., Fragoso Y., Amato M.P., Moore F., Ampapa R., Verheul F., Hodgkinson S., Cristiano E., Yamout B., Laureys G., Dominguez J.A., Zwanikken C., Deri N., Dobos E., Vrech C., Butler E., Rozsa C., Petkovska-Boskova T., Karabudak R., Rajda C., Alkhaboori J., Saladino M.L., Shaw C., Shuey N., Vucic S., Sempere A.P., Campbell J., Piroska I., Taylor B., van der Walt A., Kappos L., Roullet E., Gray O., Simo M., Sirbu C.-A., Brochet B., Cotton F., de Seze J., Dion A., Douek P., Guillemin F., Laplaud D., Lebrun-Frenay C., Moreau T., Olaiz J., Pelletier J., Rigaud-Bully C., Stankoff B., Marignier R., Debouverie M., Edan G., Ciron J., Ruet A., Collongues N., Lubetzki C., Vermersch P., Labauge P., Defer G., Cohen M., Fromont A., Wiertlewsky S., Berger E., Clavelou P., Audoin B., Giannesini C., Gout O., Thouvenot E., Heinzlef O., Al-Khedr A., Bourre B., Casez O., Cabre P., Montcuquet A., Creange A., Camdessanche J.-P., Faure J., Maurousset A., Patry I., Hankiewicz K., Pottier C., Maubeuge N., Labeyrie C., Nifle C., Brown, Will [0000-0002-7737-5834], Coles, Alasdair [0000-0003-4738-0760], Apollo - University of Cambridge Repository, McCombe, Pamela/0000-0003-2704-8517, Slee, Mark/0000-0003-4323-2453, Brown, William/0000-0002-7737-5834, Laplaud, David/0000-0001-6113-6938, Ciron, Jonathan/0000-0002-3386-6308, Roos, Izanne/0000-0003-0371-3666, Lugaresi, Alessandra/0000-0003-2902-5589, Aguera-Morales, Eduardo/0000-0002-8604-2054, Kalincik, Tomas, Girard, Marc, Patti, Francesco, Horakova, Dana, Malpas, Charles B., Olascoaga, Javier, Prevost, Julie, Roos, Izanne, Hupperts, Raymond, Csepany, Tunde, VAN WIJMEERSCH, Bart, Ferraro, Diana, Aguera-Morales, Eduardo, Cartechini, Elisabetta, Vukusic, Sandra, Frascoli, Federico, Lugaresi, Alessandra, Sa, Maria Jose, Butzkueven, Helmut, Spitaleri, Daniele, Macdonell, Richard, Coles, Alasdair, Havrdova, Eva K., Granella, Franco, Turkoglu, Recai, Trojano, Maria, Sola, Patrizia, Van Pesch, Vincent, Onofrj, Marco, Grammond, Pierre, Bergamaschi, Roberto, Izquierdo, Guillermo, McCombe, Pamela, Slee, Mark, Eichau, Sara, Prat, Alexandre, Leray, Emmanuelle, Soysal, Aysun, Terzi, Murat, Brown, J. William L., Boz, Cavit, Sidhom, Youssef, Gouider, Riadh, Ozakbas, Serkan, Casey, Romain, Lechner-Scott, Jeannette, Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Hospital Universitario Virgen Macarena [Séville], Università degli studi di Parma = University of Parma (UNIPR), University of Newcastle [Callaghan, Australia] (UoN), University of Cambridge [UK] (CAM)-Hitachi, Ltd, and ANR-10-COHO-0002,OFSEP,Observatoire Français de la Sclérose en Plaques(2010)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Time Factors ,multiple sclerosis ,law.invention ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Natalizumab ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Multiple sclerosi ,030212 general & internal medicine ,Prospective Studies ,Registries ,Prospective cohort study ,therapeutic lag ,business.industry ,Multiple sclerosis ,Interferon beta-1a ,Middle Aged ,medicine.disease ,Fingolimod ,3. Good health ,Treatment Outcome ,Cohort ,Disease Progression ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female ,Neurology (clinical) ,business ,Immunotherapies ,030217 neurology & neurosurgery ,Immunosuppressive Agents ,Therapeutic lag, prognosis, treatment ,medicine.drug ,Cohort study ,Follow-Up Studies - Abstract
In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 12 and 30 weeks. The duration of therapeutic lag for disability progression was calculated for seven therapies and ranged between 30 and 70 weeks. Significant differences in the pre- versus post-treatment annualized relapse rate were present for all therapies apart from intramuscular interferon beta-1a. In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progression in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience early on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag. This study was supported by the EDMUS Foundation, Biogen and NHMRC (1140766, 1129189, 1157717). I.R. is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The Observatoire Francais de la Sclerose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the 'Agence Nationale de la Recherche,' within the framework of the 'Investments for the Future' program, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation. The study was conducted separately and apart from the guidance of the sponsors. Kalincik, T (corresponding author), Univ Melbourne, Dept Med, CORe, 300 Grattan St, Melbourne, Vic 3050, Australia. tomas.kalincik@unimelb.edu.au
35. Alien plant species distribution in Romania: a nationwide survey following the implementation of the EU Regulation on Invasive Alien Species.
- Author
-
Anastasiu P, Miu IV, Gavrilidis AA, Preda C, Rozylowicz L, Sirbu C, Oprea A, Urziceanu M, Camen-Comanescu P, Nagoda E, Memedemin D, Barbos M, Boruz V, Cislariu A, Don I, Fagaras M, Frink JP, Georgescu IM, Haruta OI, Hurdu BI, Matis A, Milanovici S, Muncaciu S, Neacsu AG, Neblea M, Nicolin AL, Niculescu M, Oroian S, Pop OG, Radutoiu DI, Samarghitan M, Simion I, Soare LC, Steiu C, Stoianov E, Strat D, Szabo A, Szatmari PM, Tanase C, Mirea MD, Manta N, and Sirbu IM
- Abstract
Background: Biological invasions pose an increasing risk to nature, social security and the economy, being ranked amongst the top five threats to biodiversity. Managing alien and invasive species is a priority for the European Union, as outlined in the EU Biodiversity Strategy for 2030 and the Kunming-Montreal Global Biodiversity Framework. Alien plant species are acknowledged to impact the economy and biodiversity; thus, analysing the distribution of such species provides valuable inputs for the management and decision-making processes. The database presented in the current study is the first consolidated checklist of alien plant species that are present in Romania, both of European Union concern and of national interest. This database complements a prior published distribution, based only on records from literature, bringing new information regarding the occurrence of alien plants in Romania, as revealed by a nationwide field survey. We consider this database a valuable instrument for managing biological invasions at both national and regional levels, as it can be utilised in further research studies and in drafting management and action plans, assisting stakeholders in making informed decisions and implementing management actions., New Information: We present the results of the first nationwide survey of alien plant species in Romania, conducted between 2019 and 2022, in the framework of a national project coordinated by the Ministry of Environment, Waters and Forests and the University of Bucharest. The present database complements and updates the database published by Sirbu et. al (2022), which included occurrence records published until 2019. The new database includes 98323 occurrence records for 396 alien plant species in 77 families, with most species belonging to the Asteraceae family. One alien plant species in our database, the black locust Robiniapseudoacacia L., had more than 10,000 occurrence records. The distribution database also includes information on newly-reported invasive alien plant species of European Union concern in Romania (i.e. the floating primrose-willow Ludwigiapeploides (Kunth) P.H.Raven) and documents the presence of plants in 44 additional families compared to Sirbu et al. (2022). Each entry includes information on species taxonomy, location, year, person who recorded and identified the alien plant, geographical coordinates and taxon rank., (Paulina Anastasiu, Iulia V Miu, Athanasios A Gavrilidis, Cristina Preda, Laurentiu Rozylowicz, Culita Sirbu, Adrian Oprea, Mihaela Urziceanu, Petronela Camen-Comanescu, Eugenia Nagoda, Daniyar Memedemin, Marius Barbos, Violeta Boruz, Alina Cislariu, Ioan Don, Marius Fagaras, Jozsef Pal Frink, Ioana Mihaela Georgescu, Ovidiu Ioan Haruta, Bogdan-Iuliu Hurdu, Attila Matis, Sretco Milanovici, Sorana Muncaciu, Alina Georgeta Neacsu, Monica Neblea, Alma Lioara Nicolin, Mariana Niculescu, Silvia Oroian, Oliviu Grigore Pop, Daniel I Radutoiu, Mihaela Samarghitan, Ioana Simion, Liliana Cristina Soare, Corina Steiu, Emilia Stoianov, Daniela Strat, Anna Szabo, Paul Marian Szatmari, Corneliu Tanase, Marian D Mirea, Nicolae Manta, Ioana M Sirbu.)
- Published
- 2024
- Full Text
- View/download PDF
36. Introduction to the Volume: The Journey Ahead.
- Author
-
Kerr PL, Gregg JM, and Sirbu C
- Subjects
- Humans, Opioid-Related Disorders epidemiology, Analgesics, Opioid
- Abstract
The endogenous opioid system (EOS) is complex. The line of research contributing to our current body of knowledge about this system is diverse, as are the ways in which endogenous opioids affect human health and behavior. This chapter serves as an introduction to the edited volume. It includes commentary about the current public discourse related to opioids, the rationale for this book, and the unique contributions of each chapter within this volume., (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
37. The Foundational Science of Endogenous Opioids and Their Receptors.
- Author
-
Tache S, Kerr PL, and Sirbu C
- Subjects
- Animals, Humans, beta-Endorphin metabolism, Dynorphins metabolism, Enkephalins metabolism, Opioid Peptides metabolism, Analgesics, Opioid metabolism, Receptors, Opioid metabolism
- Abstract
The function of endogenous opioids spans from initiating behaviors that are critical for survival, to responding to rapidly changing environmental conditions. A network of interconnected systems throughout the body characterizes the endogenous opioid system (EOS). EOS receptors for beta-endorphin, enkephalin, dynorphin, and endomorphin underpin the diverse functions of the EOS across biological systems. This chapter presents a succinct yet comprehensive summary of the structure of the EOS, EOS receptors, and their relationship to other biological systems., (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
38. Depression, Cancer, Inflammation, and Endogenous Opioids: Pathogenic Relationships and Therapeutic Options.
- Author
-
Hancock J, Sirbu C, and Kerr PL
- Subjects
- Humans, Analgesics, Opioid therapeutic use, Depression metabolism, Depression drug therapy, Inflammation metabolism, Neoplasms metabolism, Neoplasms drug therapy, Opioid Peptides metabolism
- Abstract
Endogenous opioids and their associated receptors form a system that maintains survival by positively reinforcing behaviors that are vital to life. Cancer and cancer treatment side effects capitalize on this system pathogenically, leading to maladaptive biological responses (e.g., inflammation), as well as cognitive and emotional consequences, most notably depression. Psychologists who treat people with cancer frequently find depression to be a primary target for intervention. However, in people with cancer, the etiology of depression is unique and complex. This complexity necessitates that psycho-oncologists have a fundamental working knowledge of the biological substrates that underlie depression/cancer comorbidity. Building on other chapters in this volume pertaining to cancer and endogenous opioids, this chapter focuses on the clinical applications of basic scientific findings., (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
39. The Role of Endogenous Opioids in Cardioprotection.
- Author
-
Sirbu C
- Subjects
- Animals, Humans, Analgesics, Opioid metabolism, Cardiotonic Agents pharmacology, Heart drug effects, Opioid Peptides metabolism, Receptors, Opioid metabolism
- Abstract
The opioid system involves opioid receptors (OPRs) and endogenous opioid peptides.This chapter will focus on the distribution of OPRs in the cardiovascular system, the expression pattern in the heart, the activation by opioid peptides, and the effects of OPRs activation with potential relevance in cardiovascular performance. In the heart, OPRs are co-expressed with beta adrenergic receptors (β-ARs) in the G-protein-coupled receptor (GPCR) superfamily, functionally cross-talk with β-Ars and modify catecholamine-induced effects. They are involved in cardiac contractility, energy metabolism, myocyte survival or death, vascular resistance. The effects of the opioid system in the regulation of systemic circulation at both the central and peripheral level are presented. The pathways are discussed under physiological (i.e., aging) and pathological conditions (atherosclerosis, heart failure, essential hypertension, ischemic stress). Stimulation of OPRs not only inhibits cardiac excitation-contraction coupling, but also protects the heart against hypoxic and ischemic injury. An enhanced sensitivity to opioids of endocrine organs and neuronal systems is operative in hypertensive patients. The opioid system can be pharmacologically engaged to selectively mimic these responses via cardiac and nervous signaling. The clinical opportunities for the use of cardioprotective effects of opioids require future investigations to provide more specific details of the impact on cardiac performance and electrophysiological properties., (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
40. Integrating (Nutri-)Metabolomics into the One Health Tendency-The Key for Personalized Medicine Advancement.
- Author
-
Hotea I, Sirbu C, Plotuna AM, Tîrziu E, Badea C, Berbecea A, Dragomirescu M, and Radulov I
- Abstract
Metabolomics is an advanced technology, still under development, with multiple research applications, especially in the field of health. Individual metabolic profiles, the functionality of the body, as well as its interaction with the environment, can be established using this technology. The body's response to various external factors, including the food consumed and the nutrients it contains, has increased researchers' interest in nutrimetabolomics. Establishing correlations between diet and the occurrence of various diseases, or even the development of personalized nutrition plans, could contribute to advances in precision medicine. The interdependence between humans, animals, and the environment is of particular importance today, with the dramatic emergence and spread of zoonotic diseases, food, water and soil contamination, and the degradation of resources and habitats. All these events have led to an increase in risk factors for functional diseases, burdening global health. Thus, this study aimed to highlight the importance of metabolomics, and, in particular, nutrimetabolomics, as a technical solution for a holistic, collaborative, and precise approach for the advancement of the One Health strategy.
- Published
- 2023
- Full Text
- View/download PDF
41. Longitudinal investigation of the factor structure of the Parkinson's disease activities of daily living, interference and dependence instrument.
- Author
-
Sirbu C, Saxby BK, McNamara CW, and Deal LS
- Abstract
The Parkinson's Disease Activities of Daily Living, Interference, and Dependence Instrument© (PD-AID) is a patient-reported outcome (PRO) instrument, recently developed to assess the clinical benefit of Parkinson's Disease (PD) treatment. The PD-AID consists of morning and evening assessments, administered daily. To benefit from the full set of the repeated observations over time, analytic approaches that account for both within- and between-individual variability are required. The current study aimed to employ the advantages of exploratory Multilevel Factor Analysis (MFA) on data collected from 93 participants with moderate to advanced PD, currently using and responding to Levodopa (L-Dopa), who completed the PD-AID twice daily as part of a prospective, non-intervention, observational study for ~28 days. Average daily completion rates were comparable for the Morning and the Evening PD-AID (78% and 74%, respectively). The intraclass correlation coefficients for the Morning and Evening PD-AID items were in the range of 0.70-0.90, with an average of 0.81 for the Morning PD-AID items and 0.83 for the Evening PD-AID items, suggesting that most variability (81%-83%) in responses was due to between-individual variability. For the Morning PD-AID, one factor (including nine out of 10 Morning PD-AID items) emerged at the between-individual level and four factors (core physical actions, basic self-care activities, feeding, and interference & dependence) at the within-individual level. For the Evening PD-AID, there were four between-individual factors (basic activities of daily living ADLs, life interference, impact on planning, and emotional consequences) and five within-individual factors (basic ADLs, toileting, life interference, medication planning, and emotional impact). The factors had high reliability., Competing Interests: CS, BS, and CM are employees of Cronos Clinical Consulting Services, Inc., the entity responsible for licensing of the PD-AID, including commercial license fees for use in industry-sponsored clinical trials. LD is the lead developer of the PD-AID and an employee of Pfizer, Inc., the funding source for the research. No authors receive any licensing fees from the PD-AID., (Copyright © 2022 Sirbu, Saxby, McNamara and Deal.)
- Published
- 2022
- Full Text
- View/download PDF
42. Peppers in Diet: Genome-Wide Transcriptome and Metabolome Changes in Drosophila melanogaster .
- Author
-
Lopez-Ortiz C, Edwards M, Natarajan P, Pacheco-Valenciana A, Nimmakayala P, Adjeroh DA, Sirbu C, and Reddy UK
- Subjects
- Animals, Diet, Drosophila melanogaster genetics, Metabolome, Transcriptome, Capsicum chemistry, Capsicum genetics, Piper nigrum genetics
- Abstract
The habanero pepper ( Capsicum chinense ) is an increasingly important spice and vegetable crop worldwide because of its high capsaicin content and pungent flavor. Diets supplemented with the phytochemicals found in habanero peppers might cause shifts in an organism's metabolism and gene expression. Thus, understanding how these interactions occur can reveal the potential health effects associated with such changes. We performed transcriptomic and metabolomic analyses of Drosophila melanogaster adult flies reared on a habanero pepper diet. We found 539 genes/59 metabolites that were differentially expressed/accumulated in flies fed a pepper versus control diet. Transcriptome results indicated that olfactory sensitivity and behavioral responses to the pepper diet were mediated by olfactory and nutrient-related genes including gustatory receptors ( Gr63a , Gr66a , and Gr89a ), odorant receptors ( Or23a , Or59a , Or82a , and Orco ), and odorant-binding proteins ( Obp28a , Obp83a , Obp83b , Obp93a , and Obp99a ). Metabolome analysis revealed that campesterol, sitosterol, and sucrose were highly upregulated and azelaic acid, ethyl phosphoric acid, and citric acid were the major metabolites downregulated in response to the habanero pepper diet. Further investigation by integration analysis between transcriptome and metabolome data at gene pathway levels revealed six unique enriched pathways, including phenylalanine metabolism; insect hormone biosynthesis; pyrimidine metabolism; glyoxylate, and dicarboxylate metabolism; glycine, serine, threonine metabolism; and glycerolipid metabolism. In view of the transcriptome and metabolome findings, our comprehensive analysis of the response to a pepper diet in Drosophila have implications for exploring the molecular mechanism of pepper consumption.
- Published
- 2022
- Full Text
- View/download PDF
43. Fifteen-Year Outcomes After Valve-Sparing Aortic Root Remodelling or Exclusion of the Non-Coronary Sinus: When to Preserve the Sinuses of Valsalva?
- Author
-
Liu Y, Benzha MY, Dan P, Hubert M, Piccoli J, Lauria G, Vanhuyse F, Sirbu C, Gauchotte G, Dong N, Villemot JP, and Maureira JP
- Subjects
- Aorta, Aortic Valve, Humans, Treatment Outcome, Aortic Valve Insufficiency, Bicuspid Aortic Valve Disease, Heart Valve Prosthesis Implantation, Sinus of Valsalva
- Abstract
Background: Isolated exclusion of the non-coronary sinus (NCS) is an attractive strategy in valve-sparing aortic root surgery, which avoids the mobilisation and re-implantation of coronary ostia. However, the long-term durability of aortic valve repair and the fate of remnant sinuses of Valsalva remain unclear., Method: From January 2006 to December 2013, 29 patients underwent replacement of the ascending aorta extending to the NCS (group NCS) and 56 patients underwent a modified Yacoub procedure (group MY) in our centre by a single surgeon. Significant difference of preoperative parameters was observed between two groups in the presence of bicuspid aortic valve (41.4% vs 12.5%, p=0.002) and the diameter of the sinus of Valsalva (47.3±4.7 mm vs 51.5±4.9 mm, p=0.01)., Results: The group NCS, as compared to the group MY, was associated with significantly shorter cardiopulmonary bypass time (106.6±40.5 min vs 138.4±37.5 min, p=0.001) and aortic cross clamping time (69.0±21.8 min vs 105.4±27.8 min, p<0.01). The mean follow-up was 11.5±2.8 years. No surgical re-intervention was performed for aortopathies of the aortic root; the neo-sinus were not dilated in either groups (38.2±4.2 mm vs 34.0±4.0 mm, p<0.01). The 10-year freedom from aortic valve-related re-operation was estimated to be 96.6±3.4% and 94.5±3.1% (p=0.58), and the cumulative 10-year survival rates were 95.2±4.6% and 85.6±4.7% (p=0.61) in the group NCS and the group MY, respectively., Conclusions: Aortic valve-sparing isolated NCS replacement can be safely performed in selected patients; its early outcomes, overall survival and long-term freedom from aortic valve-related or aortopathy-related re-intervention were comparable to those obtained with the Yacoub procedure., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
44. Primary Epicardial Malt Lymphoma: A New Physiopathologic Entity Mimicking a Pericardial Compressive Syndrome.
- Author
-
Grandmougin D, Bouhlel MC, Lardenois E, Donaint P, Benigni P, Sbaffi A, Sirbu C, Feugier P, Touati R, and Maureira JP
- Abstract
MALT lymphoma is a non-Hodgkin lymphoma developing from B cells and is a type of marginal zone lymphoma. It can develop in any organs, but no case of primary cardiac location has yet been reported. We report the first observation of a primary epicardial MALT lymphoma mimicking a compressive pericardial syndrome. ( Level of Difficulty: Advanced. )., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
45. A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors.
- Author
-
Du W, Sirbu C, Lucas BD Jr, Jubelirer SJ, Khalid A, and Mei L
- Abstract
Introduction: Brain metastases (BM) are associated with dismal prognosis, and there is a dearth of effective systemic therapy. In this study, patients with BM from multiple solid tumors were identified from TriNetX databases, their clinicopathological features were evaluated, and the effects of immune checkpoint inhibitor (ICI) therapy were assessed., Methods: Variables, including median overall survival (OS), Eastern Cooperative Oncology Group (ECOG) performance status, primary diagnosis, and date of diagnosis, were retrieved from TriNetX, a real-world database. Kaplan-Meier plots and log-rank tests were applied to assess significance of differences in survival. Hazard ratio (HR) and 95% confidence interval (CI) values were calculated. All patient data were deidentified., Results: A total of 227,255 patients with BM were identified in the TriNetX database; median OS was 12.3 months from initial cancer diagnosis and 7.1 months from development of BM. OS of BM from nonsmall-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), melanoma, and renal cell carcinoma (RCC) were 8.7, 14.7, 17.8, and 15.6 months, respectively. After matching patient baseline characteristics, OS of cohorts with or without exposure to ICIs was evaluated. For all types of cancer, median OS durations for the ICI and no-ICI cohorts were 14.0 and 7.9 months, respectively (HR: 0.88; 95% CI: 0.85-0.91). More specifically, OS was remarkably prolonged in patients with NSCLC (14.4 vs . 8.2 months; HR: 0.86; 95% CI: 0.82-0.90), TNBC (23.9 vs . 11.6 months; HR: 0.87; 95% CI: 0.82-0.92), and melanoma (27.6 vs . 16.8 months; HR: 0.80; 95% CI: 0.73-0.88) if patients had exposure to ICIs. In contrast, there was no significant difference in OS of patients with RCC treated with and without ICIs (16.7 vs . 14.0 months; HR: 0.96; 95% CI: 0.86-1.10)., Conclusions: Overall, BM indicates poor patient outcome. Treatment with ICIs improves survival of patients with NSCLC, TNBC, and melanoma and BM; however, no significant improvement was observed in RCC. Investigations to identify prognostic features, oncogenomic profiles, and predictive biomarkers are warranted., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Du, Sirbu, Lucas, Jubelirer, Khalid and Mei.)
- Published
- 2021
- Full Text
- View/download PDF
46. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.
- Author
-
Annie FH, Sirbu C, Frazier KR, Broce M, and Lucas BD Jr
- Subjects
- Aged, Clinical Trials as Topic, Cohort Studies, Databases, Factual, Female, Humans, Hydroxychloroquine administration & dosage, Hydroxychloroquine adverse effects, Male, Middle Aged, Mortality trends, Retrospective Studies, Treatment Outcome, COVID-19 mortality, Drug Repositioning, Hospitalization statistics & numerical data, Hydroxychloroquine therapeutic use, Off-Label Use, COVID-19 Drug Treatment
- Abstract
Introduction: Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial., Objectives: We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up., Methods: This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded., Results: Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages ± SD were 62.3 ± 15.9 years (53.7% male) and 61.9 ± 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort's rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7)., Conclusions: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ., (© 2020 Pharmacotherapy Publications, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
47. Effect of Pepper-Containing Diets on the Diversity and Composition of Gut Microbiome of Drosophila melanogaster .
- Author
-
Garcia-Lozano M, Haynes J, Lopez-Ortiz C, Natarajan P, Peña-Garcia Y, Nimmakayala P, Stommel J, Alaparthi SB, Sirbu C, Balagurusamy N, and Reddy UK
- Subjects
- Animals, Bacteria isolation & purification, Drosophila melanogaster drug effects, Drosophila melanogaster growth & development, Female, Male, Bacteria classification, Bacteria genetics, Diet methods, Drosophila melanogaster microbiology, Gastrointestinal Microbiome drug effects, Phytochemicals pharmacology, Piper nigrum chemistry
- Abstract
One of the greatest impacts on the gastrointestinal microbiome is diet because the host and microbiome share the same food source. In addition, the effect of diet can diverge depending on the host genotype. Diets supplemented with phytochemicals found in peppers might cause shifts in the microbiome. Thus, understanding how these interactions occur can reveal potential health implications associated with such changes. This study aims to explore the gut microbiome of different Drosophila genetic backgrounds and the effects of dietary pepper treatments on its composition and structure. We analyzed the gut microbiomes of three Drosophila melanogaster genetic backgrounds (Canton-S, Oregon-RC, and Berlin-K) reared on control and pepper-containing diets (bell, serrano, and habanero peppers). Results of 16S rRNA gene sequencing revealed that the variability of Drosophila gut microbiome can be driven mainly by genetic factors. When the abundance of these communities is considered, pepper-containing diets also appear to have an effect. The most relevant change in microbial composition was the increment of Lactobacillaceae and Acetobacteraceae abundance in the pepper-containing diets in comparison with the controls in Oregon-RC and Berlin-K. Regression analysis demonstrated that this enhancement was associated with the content of phenolic compounds and carotenoids of the peppers utilized in this study; specifically, to the concentration of β-carotene, β-cryptoxanthin, myricetin, quercetin, and apigenin.
- Published
- 2020
- Full Text
- View/download PDF
48. Effect of ghost pepper on cell proliferation, apoptosis, senescence and global proteomic profile in human renal adenocarcinoma cells.
- Author
-
Perla V, Nadimi M, Reddy R, Hankins GR, Nimmakayala P, Harris RT, Valluri J, Sirbu C, and Reddy UK
- Subjects
- Capsaicin analogs & derivatives, Capsaicin pharmacology, Carcinoma, Renal Cell drug therapy, Caspases metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cellular Senescence, Gene Expression Regulation, Neoplastic drug effects, Humans, Kidney Neoplasms drug therapy, Plant Extracts chemistry, Signal Transduction drug effects, Tandem Mass Spectrometry, Capsicum chemistry, Carcinoma, Renal Cell metabolism, Kidney Neoplasms metabolism, Plant Extracts pharmacology, Proteomics methods
- Abstract
Chili peppers are an important constituent of many foods and contain medicinally valuable compounds, such as capsaicin and dihydrocapsaicin. As various dietary botanicals have anticancer properties, this study was aimed to examine the effect of Ghost pepper (Bhut Jolokia), one of the hottest chili peppers in the world, on cell proliferation, apoptosis, senescence and the global proteomic profile in human renal cell adenocarcinoma in vitro. 769-P human renal adenocarcinoma cells were cultured on RPMI-1640 media supplemented with fetal bovine serum (10%) and antibiotic-antimycotic solution (1%). Treatment stock solutions were prepared in ethanol. Cell proliferation was tested with phenol red-free media with capsaicin (0-400 μM), dihydrocapsaicin (0-400 μM), capsaicin + dihydrocapsaicin (5:1), and dry Ghost peppers (0-3 g L-1) for 24, 48 and 72 h. Polycaspase and senescence associated-beta-galactosidase (SA-beta-gal) activities were tested with capsaicin (400 μM), dihydrocapsaicin (400 μM), capsaicin (400 μM) + dihydrocapsaicin (80 μM), and ghost pepper (3 g L-1) treatments. Global proteomic profile of cells in control and ghost pepper treatment (3 g L-1) was analyzed after 6 h by a shotgun proteomic approach using tandem mass spectrometry. At 24 h after treatment (24 HAT), relative to control, cell proportion with capsaicin (400 μM), dihydrocapsaicin (400 μM), capsaicin (400 μM) + dihydrocapsaicin (80 μM), and ghost pepper (3 g L-1) treatments was reduced to 36%, 18%, 33% and 20%, respectively, and further reduced at 48 and 72 HAT. All treatments triggered an early polycaspase response. SA-beta-gal activity was normal or suppressed with all treatments. About 68,220 protein isoforms were identified by shotgun proteomic approach. Among these, about 8.2% were significantly affected by ghost pepper. Ghost pepper regulated various proteins involved in intrinsic and extrinsic apoptotic pathways, Ras, Rb/E2F, p53, TGF-beta, WNT-beta catenin, and calcium induced cell death pathways. Ghost pepper also induced changes in proteins related to methylation, acetylation, genome stability, cell cycle check points, carbohydrate, protein and other metabolism and cellular mechanisms. Ghost pepper exhibited antiproliferation activity by inducing apoptosis through a complex network of proteins in human renal cell adenocarcinoma in vitro., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
49. Combination Drug Therapy of Pioglitazone and D-cycloserine Attenuates Chronic Orofacial Neuropathic Pain and Anxiety by Improving Mitochondrial Function Following Trigeminal Nerve Injury.
- Author
-
Lyons DN, Zhang L, Pandya JD, Danaher RJ, Ma F, Miller CS, Sullivan PG, Sirbu C, and Westlund KN
- Subjects
- Animals, Anti-Anxiety Agents pharmacology, Anxiety drug therapy, Anxiety metabolism, Brain drug effects, Brain metabolism, Chronic Pain metabolism, Chronic Pain psychology, Cognition drug effects, Disease Models, Animal, Drug Therapy, Combination, Facial Pain metabolism, Facial Pain psychology, Hyperalgesia drug therapy, Hyperalgesia metabolism, Hyperalgesia psychology, Male, Mice, Inbred C57BL, Mitochondria drug effects, Mitochondria metabolism, Neuralgia metabolism, Neuralgia psychology, Random Allocation, Trigeminal Nerve Injuries metabolism, Trigeminal Nerve Injuries psychology, Analgesics pharmacology, Chronic Pain drug therapy, Cycloserine pharmacology, Facial Pain drug therapy, Neuralgia drug therapy, Pioglitazone pharmacology, Trigeminal Nerve Injuries drug therapy
- Abstract
Objectives: The study aim was to determine how peripheral trigeminal nerve injury affects mitochondrial respiration and to test efficacy of combined treatment with 2 Federal Drug Administration approved drugs with potential for improving mitochondrial bioenergetics, pain and anxiety-related behaviors in a chronic orofacial neuropathic pain mouse model., Methods: Efficacy of (R)-(+)-4-amino-3-isoxazolidinone (D-cycloserine, DCS), an N-Methyl-D-aspartate antagonist/agonist, and Pioglitazone (PIO), a selective agonist of nuclear receptor peroxisome proliferator-activated receptor gamma was investigate in the trigeminal inflammatory compression (TIC) neuropathic nerve injury mouse model. Combined low doses of these drugs (80 mg/kg DCS and 100 mg/kg PIO) were given as a single bolus or daily for 7 days post-TIC to test ability to attenuate neuropathic nociceptive and associated cognitive dependent anxiety behaviors. In addition, beneficial effects of the DCS/PIO drug combination were explored ex vivo in isolated cortex/brainstem mitochondria at 28 weeks post-TIC., Results: The DCS/PIO combination not only attenuated orofacial neuropathic pain and anxiety-related behaviors associated with trigeminal nerve injury, but it also improved mitochondrial bioenergetics., Discussion: The DCS/PIO combination uncoupled mitochondrial respiration in the TIC model to improve cortical mitochondrial dysfunction, as well as reduced nociceptive and anxiety behaviors present in mice with centralized chronic neuropathic nerve injury. Combining these drugs could be a beneficial treatment for patients with depression, anxiety, or other psychological conditions due to their chronic pain status.
- Published
- 2018
- Full Text
- View/download PDF
50. Molecular diversity and phylogeny of indigenous Rhizobium leguminosarum strains associated with Trifolium repens plants in Romania.
- Author
-
Efrose RC, Rosu CM, Stedel C, Stefan A, Sirbu C, Gorgan LD, Labrou NE, and Flemetakis E
- Subjects
- Biodiversity, Genes, Bacterial, Genes, Essential, Genome, Bacterial, Genomics methods, Molecular Typing, Multilocus Sequence Typing, Phenotype, Genetic Variation, Phylogeny, Rhizobium leguminosarum classification, Rhizobium leguminosarum genetics, Trifolium microbiology
- Abstract
The symbiotic nitrogen fixing legumes play an essential role in sustainable agriculture. White clover (Trifolium repens L.) is one of the most valuable perennial legumes in pastures and meadows of temperate regions. Despite its great agriculture and economic importance, there is no detailed available information on phylogenetic assignation and characterization of rhizobia associated with native white clover plants in South-Eastern Europe. In the present work, the diversity of indigenous white clover rhizobia originating in 11 different natural ecosystems in North-Eastern Romania were assessed by a polyphasic approach. Initial grouping showed that, 73 rhizobial isolates, representing seven distinct phenons were distributed into 12 genotypes, indicating a wide phenotypic and genotypic diversity among the isolates. To clarify their phylogeny, 44 representative strains were used in sequence analysis of 16S rRNA gene and IGS fragments, three housekeeping genes (atpD, glnII and recA) and two symbiosis-related genes (nodA and nifH). Multilocus sequence analysis (MLSA) phylogeny based on concatenated housekeeping genes delineated the clover isolates into five putative genospecies. Despite their diverse chromosomal backgrounds, test strains shared highly similar symbiotic genes closely related to Rhizobium leguminosarum biovar trifolii. Phylogenies inferred from housekeeping genes were incongruent with those of symbiotic genes, probably due to occurrence of lateral transfer events among native strains. This is the first polyphasic taxonomic study to report on the MLSA-based phylogenetic diversity of indigenous rhizobia nodulating white clover plants grown in various soil types in South-Eastern Europe. Our results provide valuable taxonomic data on native clover rhizobia and may increase the pool of genetic material to be used as biofertilizers.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.